52 Week Range
As of on the New York Stock Exchange ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
FDA Says Boston Scientific Recalls Ingenio Family Of Pacemakers And Crt-Ps Due To Risk Of Transition To Safety Mode
FDA Says Boston Scientific Recalling Ingenio Family Of Pacemakers And CRT-Ps
Boston Scientific Reports Q2 Earnings Per Share $0.12
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by businesses such Interventional Cardiology, Peripheral Interventions, Cardiac Rhythm Management, Electrophysiology, Endoscopy, Urology and Pelvic Health, Neuromodulation and Specialty Pharmaceuticals. It operates in three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. MedSurg consists of Endoscopy and Urology and Pelvic Health businesses. Rhythm segment consists of Cardiac Rhythm Management, Electrophysiology and Neuromodulation businesses. Its Cardiovascular segment consists of Interventional Cardiology and Peripheral Interventions businesses. Its product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters, embolic protection devices and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures.
Medical Equipment & Supplies
300 BOSTON SCIENTIFIC WAY
Michael F. Mahoney
Chairman of the Board, President, Chief Executive Officer
Daniel J. Brennan
Chief Financial Officer, Executive Vice President
Arthur C. Butcher
Executive Vice President and President, Asia Pacific
Joseph M. Fitzgerald
Executive Vice President, President, Interventional Cardiology
Edward F. Mackey
Executive Vice President - Global Operations
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Boston Scientific Corp, after being sanctioned for discovery violations in a whistleblower lawsuit over allegedly defective defibrillators, has been ordered to pay the plaintiff about $68,400 in fees and expenses related to the sanctions motion.
Boston Scientific Corp has won summary judgment against a long-running whistleblower lawsuit accusing it of selling defective implantable cardiac defibrillators.
McDonald's Corp on Monday said it hired Desiree Ralls-Morrison as general counsel and corporate secretary.
Boston Scientific Corp agreed to pay $188.7 million to settle claims by most U.S. states that it deceptively marketed its surgical mesh devices to consumers.
Boston scientific confirms multistate settlement over surgical mesh devices, and says it is not an admission of misconduct or liability
Boston Scientific Corp agreed to pay nearly $189 million to settle claims by most U.S. states that it misled consumers about the safety and effectiveness of its surgical mesh devices.
New York's attorney general on Tuesday filed a lawsuit accusing Boston Scientific Corp of concealing the risks of its surgical mesh devices.
Boston Scientific Corp has agreed to buy the global surgical business of privately held Lumenis Ltd for $1.07 billion in cash, as the medical device maker looks to add an array of laser systems used in treating kidney stones to its portfolio.
Medical device maker Boston Scientific Corp said on Wednesday it would buy the global surgical business of privately-held Lumenis Ltd for $1.07 billion in cash from Baring Private Equity Asia. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Ramakrishnan M.)
* SAYS MANY COUNTRIES RETURNED TO YEAR-OVER-YEAR GROWTH IN Q3- CONF. CALL
Boston Scientific Corp <BSX.N> swung to a loss in the third quarter from profit a year ago, as demand for its medical devices was hurt by the ongoing COVID-19 pandemic.
Boston Scientific Corp reported a third-quarter loss on Wednesday, hurt by lower demand for its medical devices.
Boston Scientific Corp, after being sanctioned for discovery violations in a whistleblower lawsuit over allegedly defective defibrillators and ordered to pay the plaintiff's legal fees for the sanctions motion, has accused the whistleblower of demanding "excessive" fees...
Medical device maker Boston Scientific Corp <BSX.N> on Wednesday posted a surprise adjusted quarterly profit and said demand for elective procedures picked up pace in July following an easing of coronavirus-driven restrictions.
* EXEC SAYS JULY TRENDS ARE NICELY IMPROVING FROM JUNE LEVELS- CONF. CALL
Medical device maker Boston Scientific Corp reported a second-quarter loss on Wednesday, hurt by lower demand for specialty medical devices as patients continued to defer elective procedures during the COVID-19 pandemic.
* BOSTON SCIENTIFIC CORP - KEVIN BALLINGER RESIGNING TO TAKE CEO POSITION AT CO THAT DOES NOT COMPETE WITH BOSTON SCIENTIFIC Source text for Eikon: https://bit.ly/2XLd0hW Further company coverage:
* BOSTON SCIENTIFIC RECEIVES MEDICARE TRANSITIONAL PASS-THROUGH PAYMENT FOR THE EXALT™ MODEL D SINGLE-USE DUODENOSCOPE Source text for Eikon: Further company coverage:
* BOSTON SCIENTIFIC LAUNCHES DIRECTSENSE™ TECHNOLOGY Source text for Eikon: Further company coverage:
* BOSTON SCIENTIFIC - ON MAY 28 ENTERED INTO SECOND AMENDMENT TO ITS $1 BILLION 364-DAY TERM LOAN CREDIT AGREEMENT
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.